Cyclist With MS Embarks on Cross-Country Trek for Awareness

2007-08-31 21:03:50

Cyclist With MS Embarks on Cross-Country Trek for Awareness

2004-01-20 11:50 ET - News Release

MONTVILLE, N.J., Jan. 20 /PRNewswire/ -- Fourteen thousand miles on a bike -- that's nothing for Delbert Richardson. The 50-year-old Wichita resident already cycled across the United States three years ago, traveling through 17 states from Seattle to Washington, D.C.

http://new.stockwatch.com/newsit/newsit_newsit.pasp?bid=U-pNYTU156-U:SHR-20040120&symbol=SHR&news_region=U&name=SCHERING+AKTIENGESELLSCHA&title=Cyclist

[INLINE]

~Joyce [INLINE]
If Barbie is so popular, why do you have to buy her friends?

Fw: Discover The Latest Advances in MS - Webcast

2007-08-31 16:45:48

-----Forwarded Message-----
From: "Multiplesclerosis.com" <support@...
Sent: Jan 20, 2004 7:45 AM
To: jayneadler@...
Subject: Discover The Latest Advances in MS - Webcast
<html
<body bgcolor="#ffffcc" text="#13437b" leftmargin="12" topmargin="0"
marginwidth="0" marginheight="0" style="FONT-FAMILY: "
<table width="505" border="0" cellspacing="0" cellpadding="0"
<tr
<td
<table width="519" border="0" cellspacing="0" cellpadding="0"
height="20"
<tr
<td width="192" valign="top"
src="http://www.multiplesclerosis.com/images/VIOLATOR.gif" width="97"
height="76"
<td width="137"
src="http://www.multiplesclerosis.com/images/ms_dot_com_logo.gif" width="150"
height="76"
<td width="190"
</tr
</table
</center
</tr
<tr
<td
<h2 align="center"
sans-serif"
Presents:</font
<p align="center"
sans-serif"
the Complexities of Multiple Sclerosis</b
An Interactive Webcast Series<br
for People With Multiple Sclerosis and Their Families</font
<p align="center"
Tuesday, January 20, 2004<br
Time: 6:30 PM EST</b
<p align="center"
Register,
Log Onto <a
href="http://rm.resultsmail.com/route.cfm?mid=fcd67785-a4d8-4fe4-b829-fdd6e021b6\
8e&uid=87c2470b-01ca-4abb-989c-3deb8282a997&route=http%3A%2F%2Fwww%2Emultiplescl\
erosis%2Ecom%2Fwebcast%2Ehtm"
face="Arial, Helvetica, sans-serif"
<i
again.</i
<br
</b
<table width="80%" border="1" cellspacing="0" cellpadding="0"
align="center"
<tr
<td bordercolor="#000099"
<div align="center"
<p
Early Axonal Loss</b
<i
</font
<p
Perspective</b
June Halper, MSCN, ANP, FAAN</i
<br
</b
</div
</td
</tr
<tr
<td bgcolor="#abd2e5" bordercolor="#000099" width="80%"
<div align="center"
PRESENTATIONS WILL BE FOLLOWED BY A<br
QUESTION-AND-ANSWER SESSION.</b
</td
</tr
</table
<p align="center"
RSVP Today</b
<p align="center"
Register,
Log Onto <a
href="http://rm.resultsmail.com/route.cfm?mid=fcd67785-a4d8-4fe4-b829-fdd6e021b6\
8e&uid=87c2470b-01ca-4abb-989c-3deb8282a997&route=http%3A%2F%2Fwww%2Emultiplescl\
erosis%2Ecom%2Fwebcast%2Ehtm"
</b
<hr width="75%" color="#13437b"
<p align="left"
have access to the Web and would still like to participate, please call
800-906-4412 to register. Please note that phone access is limited. You
will receive call-in information prior to the Webcast.<b
</b
<p align="center"
program is sponsored by an unrestricted educational grant from Berlex
Laboratories.</font
<br
</p
</td
</tr
</table
<img
src="http://rm.resultsmail.com/invisGif.cfm?mid=fcd67785-a4d8-4fe4-b829-fdd6e021\
b68e&uid=87c2470b-01ca-4abb-989c-3deb8282a997" height="1" width="1"
<style
pt;color:#000000;font-weight:normal;background-color:#FFFFFF;};A.rmLink:link{fon\
t-family:Verdana,Geneva,Arial,Helvetica,sans-serif;font-size:7pt;font-weight:nor\
mal;color:
#444444;};A.rmLink:visited{font-family:Verdana,Geneva,Arial,Helvetica,sans-serif\
;font-size:7pt;font-weight:normal;color:
#444444;};A.rmLink:hover{font-family:Verdana,Geneva,Arial,Helvetica,sans-serif;f\
ont-size:7pt;font-weight:normal;color: #AD1835;}</style
cellpadding="5" cellspacing="0"
width="100%"
bgcolor="#FFFFFF"
href=" http://www.avee-health.com" class="rmLink"
Health Strategies</font
10003 United States <br
wish <BR
href="http://rm.resultsmail.com/unsubscribe.cfm?mid=fcd67785-a4d8-4fe4-b829-fdd6\
e021b68e&uid=87c2470b-01ca-4abb-989c-3deb8282a997&route=http%3A%2F%2Frm%2Eresult\
smail%2Ecom%2Funsubscribed%2Ecfm" class="rmLink"
here</font
by<br
href="http://www.resultsmail.com/index.cfm?mid=fcd67785-a4d8-4fe4-b829-fdd6e021b\
68e" class="rmLink"
border="0" alt="ResultsMail"
href="http://www.resultsmail.com/privacy" class="rmLink"
color="#444444"
href="http://www.resultsmail.com/permission" class="rmLink"
color="#444444"
class="rmText"
X-mTrak-mID: fcd67785-a4d8-4fe4-b829-fdd6e021b68e
<BR
X-mTrak-cID: 87c2470b-01ca-4abb-989c-3deb8282a997
</span

Re: [MS_Community] Trying to get my address book in order

2007-08-31 15:08:08

Hi Jayne,

Today's date 1/20/04

Regards,

Tom

Trying to get my address book in order

2007-08-31 03:29:22

If you want to make sure I have your addy for the

The choices you make

2007-08-30 23:44:53

Tuesday, January 20, 2004

The choices you make

Many of the things that bring you down are of your own choosing. You choose them because you assume there is nothing better available to you, but there is always something better.

Many of the things that bring you down are just old habits that you have never managed to break. You assume they are a permanent part of you, but they are not.

Sure, it takes some effort to find and make better choices, yet those choices are indeed there. Once you begin to find a few new ways many more will suddenly pop into view.

Yes, it takes time and commitment to overcome a destructive habit. Once you do it, though, you will feel as if you can take on just about any challenge, and you will be right.

Think about who you really are and what you truly want to do with your life. Let your best vision of who you are, and of who you can be, guide the choices that you make every moment.

Life can be easy, haphazard and empty, or it can be focused, directed and full. The choices you make will develop into who you choose to be.

-- Ralph Marston

[INLINE]

~Joyce [INLINE]
If Barbie is so popular, why do you have to buy her friends?

Fw: Taking Vitamin D Supplements Lowers Risk of Multiple Sclerosis

2007-08-30 16:54:51

-----Forwarded Message-----
From: Doctor's Guide <weeklyedition@...
Sent: Jan 19, 2004 5:50 PM
To: Jayne Adler <jayneadler@...
Subject: Taking Vitamin D Supplements Lowers Risk of Multiple Sclerosis
<HTML
content="text/html; charset=iso-8859-1"
marginheight="0" marginwidth="0" topmargin="0" leftmargin="0" text="#000000"
name=top
ALIGN="CENTER"
sans-serif" size="1" color="gray"
days</font
sans-serif"
Sclerosis
</headline
supplements through multivitamins are 40 percent less likely to develop multiple
sclerosis (MS) than women who do not take supplements, according to a study
published in the January 13 issue of Neurology , the scientific journal of the
American Academy of Neurology. Food is a source of ...<a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=22&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&ntype=int&newsid=8525697700573E1885256E\
1A004DBD08"
WIDTH="300" ALIGN="center" VALIGN="MIDDLE"
href="http://www.docguide.com/dgc.nsf/us/Jayne.Adler.834"
src="http://www.docguide.com/gpimgs/htmlemail/DGweekly.gif"
border="0"
WIDTH="5"
Helvetica, Sans Serif" size="4" color="red"
face="Arial, Helvetica, Sans Serif" size="1"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=12&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/register?OpenForm\
&n=yes&lan=English"
here</a
CELLPADDING="0" CELLSPACING="0" width="100%"
valign="middle" align="left"
color="#ffffff"
days</b
sans-serif" size="1" color="gray"
most read by your colleagues in the past 7 days</font
<font size="2" face="Verdana,Arial,Helvetica,sans-serif"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E180037A3F7"
inhibitor</a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E17003AE016"
organ transplantation?</a
Am</b
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1700325CAB"
an increased risk for chronic renal insufficiency in patients with lupus
nephritis</a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1A00320AE1"
HLA-mismatched family donors for acute leukemia: single-center experience of 201
patients</a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1A0032094C"
allogeneic stem cell transplantation for renal cell carcinoma are associated
with expansion of CD8(+) IFN-gamma-producing T cells</a
Marrow Transplant</b
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E170031FF99"
<i
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1800318F41"
and update</a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1B003AA05B"
erythematosus</a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1B003AA32D"
revisited</a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1800318409"
improves the treatment of chronic urticaria in patients with positive autologous
serum skin test results</a
Immunol</b
</ul
color="gray"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=51&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllSpecN\
ews?OpenForm&dt=s&id=A90C2AB8E952068E85256CEE00054A8C&specialty=Immunology"
news...</a
size="1" color="gray"
Immunology were added to the DG database. For a full list <a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=51&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllSpecN\
ews?OpenForm&dt=s&id=A90C2AB8E952068E85256CEE00054A8C&specialty=Immunology"
k here</a
</font
width="100%"
face="Arial, Helvetica, Sans Serif" size="2" color="#ffffff"
Immunology news in the past 3 months</b
face="Verdana, Arial, Helvetica, sans-serif" size="1" color="gray"
articles, pertaining to Immunology, most read by your colleagues in the past 3
months</font
<font size="2" face="Verdana,Arial,Helvetica,sans-serif"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256DA9005C1722"
erythematosus</a
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&ntype=int&newsid=8525697700573E1885256D\
760034E12B"
immunodeficiency virus infection in adolescents</a
Pediatr</b
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=22&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&ntype=int&newsid=8525697700573E1885256D\
760034E12B"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256D8600331393"
syndrome: recommendations for treatment. Committee consensus report</a
<i
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256DA1003AC272"
respiratory syndrome with fatal outcome</a
Singapore</b
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256DC500756DA1"
Pediatr</b
Helvetica, sans-serif" size="2"
page</a
<font color="black" size="2" face="Arial, Verdana, Helvetica, Sans Serif"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=3&id=A90C2AB8E952068E\
85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/Contactus?Openform\
&id=A90C2AB8E952068E85256CEE00054A8C&loc=PE"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=4&id=A90C2AB8E952068E\
85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/web-journals?OpenF\
orm&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=41&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/RegisterAColleagu\
e?OpenForm&id=A90C2AB8E952068E85256CEE00054A8C"
colleague</nobr
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=7&id=A90C2AB8E952068E\
85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/reminder.nsf/Reminder?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&email=y"
Me</nobr
face="Arial"
Copyright (c) 1995-2004 Doctor's Guide Publishing Limited. All rights reserved.
</font
VALIGN="TOP"
cellpadding="15" cellspacing="0" align="center" bgcolor="#f3f3f3"
border="0" width="90%" cellpadding="0" cellspacing="0"
align="center"
size="2"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=30&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/us/Jayne.Adler.83\
4"
GUIDE</b
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=1407&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/web-top5?OpenFo\
rm&id=A90C2AB8E952068E85256CEE00054A8C"
News</font
</font
FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=17&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllNews?\
OpenForm&dt=s&abd=yes&id=A90C2AB8E952068E85256CEE00054A8C"
size="2"
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=18&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllWebca\
st?OpenForm&abd=yes&id=A90C2AB8E952068E85256CEE00054A8C"
size="2"
valign="top"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=19&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllCases\
?OpenForm&abd=yes&id=A90C2AB8E952068E85256CEE00054A8C"
size="2"
SIZE="1" COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=20&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/crc.nsf/web-bySpecDisp?Op\
enForm"
Center</font
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=21&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/MedicalR\
esourcesWeb?OpenForm&id=A90C2AB8E952068E85256CEE00054A8C"
size="2"
Resources</font
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=20&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=crc.nsf/web-bySpecDisp?Ope\
nForm&spec=Immunology"
src="http://www.docguide.com/gpimgs/htmlemail/uscrc_info.gif"
border="0"
<table border="0" width="90%" cellpadding="0" cellspacing="0"
align="center"
size="2"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=25&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/us/Jayne.Adler.83\
4?OpenDocument&email=personalise"
size="2"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=25&id=id=A90C2AB8E952\
068E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/Personalize?Op\
enForm&id=A90C2AB8E952068E85256CEE00054A8C&p=yes&email=y"
src="http://www.docguide.com/gpimgs/main/smallp.gif" border="0"
alt=""
FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/dgc.nsf/EditName?openForm&id=A90C2AB8E952068E85256\
CEE00054A8C&p=yes&email=y"
E-Mail</font
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/dgc.nsf/EditWebSearch?OpenForm&id=A90C2AB8E952068E\
85256CEE00054A8C&p=yes&email=y"
Search Engine</font
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/dgc.nsf/EmailLogin?OpenForm&id=A90C2AB8E952068E852\
56CEE00054A8C&p=yes&email=y"
Account</font
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=16&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/EditConditions?Op\
enForm&id=A90C2AB8E952068E85256CEE00054A8C&p=yes&email=y"
size="2"
SIZE="1" COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/dgc.nsf/editlang?OpenForm&p=yes&id=A90C2AB8E952068\
E85256CEE00054A8C&email=y"
Language</font
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=14&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/us/Jayne.Adler.83\
4?OpenDocument&email=journals"
Journals</font
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=15&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/EditFavorites?Ope\
nForm&id=A90C2AB8E952068E85256CEE00054A8C&email=y"
size="2"
Sites</font
name="SearchForm" method="get"
action="http://www.docguide.com/stats/searchChannels.nsf/DocEmail"
border="1" bordercolor="#6699FF" width="100%" cellpadding="5" cellspacing="0"
align="center" bgcolor="#f3f3f3"
Helvetica, Sans Serif" size="2"
color="#0066cc"
name="CreateDocument" value="&"
maxlength="50"
name="searchbox" value="All DG"
value="G"
value="A90C2AB8E952068E85256CEE00054A8C"
value="1261935"
value="USEnglish"
value="192.168.2.171"
<table border="1" bordercolor="#6699FF" width="300" cellpadding="15"
cellspacing="0" align="center" bgcolor="#f3f3f3"
width="90%" cellpadding="0" cellspacing="0" align="center"
face="Arial, Verdana, Helvetica, Sans Serif" size="2"
size="2"
valign="top"
<font color="blue" size="2"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=5280&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/channe\
l?OpenForm&c=AIDS%20and%20HIV&id=A90C2AB8E952068E85256CEE00054A8C"
HIV</a
FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=5280&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/channe\
l?OpenForm&c=Immunology&id=A90C2AB8E952068E85256CEE00054A8C"
t
FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=5280&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/channe\
l?OpenForm&c=Lupus&id=A90C2AB8E952068E85256CEE00054A8C"
/td
FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=5280&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/channe\
l?OpenForm&c=Multiple%20Sclerosis&id=A90C2AB8E952068E85256CEE00054A8C"
Sclerosis</a
COLOR="blue" FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=5280&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/channe\
l?OpenForm&c=SARS&id=A90C2AB8E952068E85256CEE00054A8C"
d
FACE="Verdana,Arial,Helvetica"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=5280&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/channe\
l?OpenForm&c=Vaccinology&id=A90C2AB8E952068E85256CEE00054A8C"
ont
Verdana, Helvetica, Sans Serif" size="1"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=2&id=A90C2AB8E952068E\
85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/html/warning.htm?O\
penDocument&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=48&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/html/privacy.htm?\
OpenDocument&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://main.pslgroup.com/gpc.nsf/doc?CreateDocument&n=48&id=A90C2AB8E95206\
8E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=GOTO//main.pslgroup.com/p\
sl.nsf/html/about_us.html"
href="http://www.docguide.com/dgc.nsf/EmailEditionCenter?OpenForm&id=A90C2AB8E95\
2068E85256CEE00054A8C"
href="http://www.docguide.com/dgc.nsf/EmailEditionCenter?openForm&id=A90C2AB8E95\
2068E85256CEE00054A8C"
future, click here</a
COLSPAN="3"
src="http://www.docguide.com/htmlemail.gif?dn=1261935&no=01-19-2004w"
tml

Re: [MS_Community] Fw: Taking Vitamin D Supplements Lowers Risk of Multiple Sclerosis

2007-08-30 13:26:12

I apologize for the continued cyberconfusion. I'm
working on resolving this.
Jayne

href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=22&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&ntype=int&newsid=8525697700573E1885256E\
1A004DBD08"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=12&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/register?OpenForm\
&n=yes&lan=English"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E180037A3F7"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E17003AE016"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1700325CAB"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1A00320AE1"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1A0032094C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E170031FF99"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1800318F41"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1B003AA05B"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1B003AA32D"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256E1800318409"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=51&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllSpecN\
ews?OpenForm&dt=s&id=A90C2AB8E952068E85256CEE00054A8C&specialty=Immunology"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=51&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllSpecN\
ews?OpenForm&dt=s&id=A90C2AB8E952068E85256CEE00054A8C&specialty=Immunology"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256DA9005C1722"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&ntype=int&newsid=8525697700573E1885256D\
760034E12B"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=22&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&ntype=int&newsid=8525697700573E1885256D\
760034E12B"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256D8600331393"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256DA1003AC272"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=95&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/redirect.nsf/we_link?Open\
Form&refid=290&specid=105&id=A90C2AB8E952068E85256CEE00054A8C&ntype=ext&newsid=8\
525697700573E1885256DC500756DA1"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=3&id=A90C2AB8E952068E\
85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/Contactus?Openform\
&id=A90C2AB8E952068E85256CEE00054A8C&loc=PE"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=4&id=A90C2AB8E952068E\
85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/web-journals?OpenF\
orm&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=41&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/RegisterAColleagu\
e?OpenForm&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=7&id=A90C2AB8E952068E\
85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/reminder.nsf/Reminder?Open\
Form&id=A90C2AB8E952068E85256CEE00054A8C&email=y"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=30&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/us/Jayne.Adler.83\
4"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=1407&id=A90C2AB8E9520\
68E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/dgc.nsf/web-top5?OpenFo\
rm&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=17&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllNews?\
OpenForm&dt=s&abd=yes&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=18&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllWebca\
st?OpenForm&abd=yes&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=19&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/AllCases\
?OpenForm&abd=yes&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=20&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/crc.nsf/web-bySpecDisp?Op\
enForm"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=21&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=/news/content.nsf/MedicalR\
esourcesWeb?OpenForm&id=A90C2AB8E952068E85256CEE00054A8C"
href="http://www.docguide.com/gpc.nsf/doc?CreateDocument&n=20&id=A90C2AB8E952068\
E85256CEE00054A8C&t=00-00-00;AM&l=email-01-19-2004w&u=crc.nsf/web-bySpecDisp?Ope\
nForm&spec=Immunology"
src="http://www.docguide.com/gpimgs/htmlemail/uscrc_info.gif"
=== message truncated ===

Treatment of Multiple Sclerosis using Over the Counter Inosine

2007-08-30 05:27:45

http://www.clinicaltrials.gov/ct/show/NCT00067327?order=1

ClinicalTrials.gov
skipnav Home | Search | Browse | Resources | Help | What's New | About

Treatment of Multiple Sclerosis using Over the Counter Inosine

This study is currently recruiting patients.

Sponsored by

National Center for Complementary and Alternative Medicine (NCCAM)

Purpose

The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting Multiple Sclerosis (RRMS) and secondary progressive Multiple Sclerosis (MS).
Condition Treatment or Intervention Phase
Multiple Sclerosis, Relapsing-Remitting
Drug: Inosine
Phase II

MEDLINEplus related topics: Multiple Sclerosis

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further Study Details:

Uric acid is a natural inhibitor of certain chemistries associated with peroxynitrite, a product of inflammation. In animal models of multiple sclerosis (MS), these chemical reactions have been associated with breakdown of the blood-brain barrier and CNS tissue damage. In addition, MS patients have serum uric acid levels that are lower than age- and sex- matched healthy individuals. The primary purpose of this study to determine whether raising low serum uric acid levels by daily oral administration of its precursor inosine has an effect on the cumulative number of newly active lesions on magnetic resonance imaging (MRI) and to evaluate the safety and tolerability of inosine in patients diagnosed with relapsing remitting and secondary progressive MS.

Eligibility

Ages Eligible for Study: 18 Years - 60 Years, Genders Eligible for Study: Both

Criteria

Inclusion Criteria:
* Nonpregnant, nonlactating females
* Females of child bearing potential must have a negative human chorionic gonadotropin (HCG) test result within 60 days before the first dose of study material.
* Males and females must practice adequate contraception, in the judgement of the investigator, during the course of the study.
* Subjects must have a diagnosis of clinically definite Relapsing Remitting Multiple Sclerosis based on medical history, physical examination, laboratory test results, and neurologic examination. Alternatively, subjects may have clinically probable MS characterized by 1 attack and the presence of at least 4 lesions on MRI within 12 months before the initial baseline evaluation.
* Subjects must have an Expanded Disability Status Scale (EDSS) test result of less than or equal to 5.0 within 60 days before the first dose of study material.
* Subjects will have serum uric acid levels less than 5 mg/dl.
* Have 1 clinical relapse in the last year

Exclusion Criteria:
* Presence of any medical disability or laboratory test result that, in the judgement of the investigator, would interfere with assessment of the tolerability, safety, or efficacy of study material or would compromise the subject's ability to provide informed consent.
* Evidence of active infection characterized by requiring treatment with antibiotics within 7 days before the first dose of study material.
* Treatment with interferons, glatiramer acetate, lymphoid irradiation, cyclophosphamide, or with other immune modifying treatments within 3 months, or corticosteroids within 1 month before the initial baseline MRI assessment in this trial.
* Recent history (within the previous 2 years) of drug or alcohol abuse.
* Known allergy to Inosine products or history of anaphylaxis.
* Previous randomization into this study.
* Treatment with an investigational agent within 30 days before the first dose of study material.

Expected Total Enrollment: 30

Location and Contact Information
Tara Ordille, BS 215-662-4893 tara.ordille@...
Pennsylvania
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States; Recruiting
Tara Ordille, BS 215-662-4893 tara.ordille@...
Study chairs or principal investigators
Clyde E Markowitz, MD, Principal Investigator, University of Pennsylvania
Hilary Koprowski, MD, Study Director, Department of Microbiology and Immunology, Thomas Jefferson University

More Information

Click here for more information about the Inosine study.

Publications

Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):675-80.

Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, Spitsin SV. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 2000 Apr;14(5):691-8.

Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol. 2001 Jan;49(1):139. No abstract available.

Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler. 2001 Oct;7(5):313-9.
Study ID Numbers R21 AT001301-01A1
Study Start Date February 2002; Estimated Completion Date December 2004
Record last reviewed August 2003
NLM Identifier NCT00067327
ClinicalTrials.gov processed this record on 2004-01-16
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act

Can MS be Treated?

2007-08-30 01:17:12

http://www.personalhealthzone.com/multiplesclerosistreatment.html

Can MS be Treated?

There is as yet no cure for MS. Many patients do well with no therapy at all, especially since many medications have serious side effects and some carry significant risks. Naturally occurring or spontaneous remissions make it difficult to determine therapeutic effects of experimental treatments; however, the emerging evidence that MRIs can chart the development of lesions is already helping scientists evaluate new therapies.

Until recently, the principal medications physicians used to treat MS were steroids possessing anti-inflammatory properties; these include adrenocorticotropic hormone (better known as ACTH), prednisone, prednisolone, methylprednisolone, betamethasone, and dexamethasone. Studies suggest that intravenous methylprednisolone may be superior to the more traditional intravenous ACTH for patients experiencing acute relapses; no strong evidence exists to support the use of these drugs to treat progressive forms of MS. Also, there is some indication that steroids may be more appropriate for people with movement, rather than sensory, symptoms.

While steroids do not affect the course of MS over time, they can reduce the duration and severity of attacks in some patients. The mechanism behind this effect is not known; one study suggests the medications work by restoring the effectiveness of the blood/brain barrier. Because steroids can produce numerous adverse side effects (acne, weight gain, seizures, psychosis), they are not recommended for long-term use.

One of the most promising MS research areas involves naturally occurring antiviral proteins known as interferons. Two forms of beta interferon (Avonex and Betaseron) have now been approved by the Food and Drug Administration for treatment of relapsing-remitting MS. A third form (Rebif) is marketed in Europe. Beta interferon has been shown to reduce the number of exacerbations and may slow the progression of physical disability. When attacks do occur, they tend to be shorter and less severe. In addition, MRI scans suggest that beta interferon can decrease myelin destruction.

Investigators speculate that the effects of beta interferon may be due to the drug's ability to correct an MS-related deficiency of certain white blood cells that suppress the immune system and/or its ability to inhibit gamma interferon, a substance believed to be involved in MS attacks. Alpha interferon is also being studied as a possible treatment for MS. Common side effects of interferons include fever, chills, sweating, muscle aches, fatigue, depression, and injection site reactions.

Scientists continue their extensive efforts to create new and better therapies for MS. Goals of therapy are threefold: to improve recovery from attacks, to prevent or lessen the number of relapses, and to halt disease progression. Some therapies currently under investigation are discussed below.

Immunotherapy

As evidence of immune system involvement in the development of MS has grown, trials of various new treatments to alter or suppress immune response are being conducted. These therapies are, at this time, still considered experimental.

Results of recent clinical trials have shown that immunosuppressive agents and techniques can positively (if temporarily) affect the course of MS; however, toxic side effects often preclude their widespread use. In addition, generalized immunosuppression leaves the patient open to a variety of viral, bacterial, and fungal infections.

Over the years, MS investigators have studied a number of immunosuppressant treatments. Among the therapies being studied are cyclosporine (Sandimmune), cyclophosphamide (Cytoxan), methotrexate, azathioprine (Imuran), and total lymphoid irradiation (a process whereby the MS patient's lymph nodes are irradiated with x-rays in small doses over a few weeks to destroy lymphoid tissue, which is actively involved in tissue destruction in autoimmune diseases). Inconclusive and/or contradictory results of these trials, combined with the therapies' potentially dangerous side effects, dictate that further research is necessary to determine what, if any, role they should play in the management of MS. Studies are also being conducted with the immune system modulating drugs linomide (Roquinimex), cladribine (Leustatin), and mitoxantrone.

Two other experimental treatments â one involving the use of monoclonal antibodies and the other involving plasma exchange, or plasmapheresis â may have fewer dangerous side effects. Monoclonal antibodies are identical, laboratory-produced antibodies that are highly specific for a single antigen. They are injected into the patient in the hope that they will alter the patient's immune response. Plasmapheresis is a procedure in which blood is removed from the patient, and the plasma is separated from other blood substances, which may contain antibodies and other immmunologically active products. These other blood substances are discarded and the plasma is then transfused back into the patient. Because their worth as treatments for MS has not yet been proven, these experimental treatments remain at the stage of clinical testing.

Bone marrow transplantation (a procedure in which bone marrow from a healthy donor is infused into patients who have undergone drug or radiation therapy to suppress their immune system so they will not reject the donated marrow) and injections of venom from honey bees are also being studied. Each of these therapies carries the risk of potentially severe side effects.
H5

Because the transmission of electrochemical messages between the brain and body is disrupted in MS, medications to improve the conduction of nerve impulses are being investigated. Since demyelinated nerves show abnormalities of potassium activity, scientists are studying drugs that block the channels through which potassium moves, thereby restoring conduction of the nerve impulse. In several small experimental trials, derivatives of a drug called aminopyridine temporarily improved vision, coordination, and strength when given to MS patients who suffered from both visual symptoms and heightened sensitivity to temperature. Possible side effects of these therapies include paresthesias (tingling sensations), dizziness, and seizures.

H5

Trials of a synthetic form of myelin basic protein, called copolymer I (Copaxone), have shown promise in treating people in the early stages of relapsing-remitting MS. Copolymer I, unlike so many drugs tested for the treatment of MS, seems to have few side effects. Recent trial data indicate that copolymer I can reduce the relapse rate by almost one third. In addition, patients given copolymer I were more likely to show neurologic improvement than those given a placebo. The Food and Drug Administration has made the drug available to people with early relapsing-remitting MS through its "Treatment IND" program and is currently reviewing data from a large-scale study to determine whether or not to approve the drug for marketing.

Investigators are also looking at the possibility of developing an MS vaccine. Myelin-attacking T cells were removed, inactivated, and injected back into animals with experimental allergic encephalomyelitis (EAE). This procedure results in destruction of the immune system cells that were attacking myelin basic protein. In a couple of small trials scientists have tested a similar vaccine in humans. The product was well-tolerated and had no side effects, but the studies were too small to establish efficacy. Patients with progressive forms of MS did not appear to benefit, although relapsing-remitting patients showed some neurologic improvement and had fewer relapses and reduced numbers of lesions in one study. Unfortunately, the benefits did not last beyond two years.

A similar approach, known as peptide therapy, is based on evidence that the body can mount an immune response against the T cells that destroy myelin, but this response is not strong enough to overcome the disease. To induce this response, the investigator scans the myelin-attacking T cells for the myelin-recognizing receptors on the cells' surface. A fragment, or peptide, of those receptors is then injected into the body. The immune system "sees" the injected peptide as a foreign invader and launches an attack on any myelin-destroying T cells that carry the peptide. The injection of portions of T cell receptors may heighten the immune system reaction against the errant T cells much the same way a booster shot heightens immunity to tetanus. Or, peptide therapy may jam the errant cells' receptors, preventing the cells from attacking myelin.

Despite these promising early results, there are some major obstacles to developing vaccine and peptide therapies. Individual patients' T cells vary so much that it may not be possible to develop a standard vaccine or peptide therapy beneficial to all, or even most, MS patients. At this time, each treatment involves extracting cells from each individual patient, purifying the cells, and then growing them in culture before inactivating and chemically altering them. This makes the production of quantities sufficient for therapy extremely time consuming, labor intensive, and expensive. Further studies are necessary to determine whether universal inoculations can be developed to induce suppression of MS patients' overactive immune systems.

Protein antigen feeding is similar to peptide therapy, but is a potentially simpler means to the same end. Whenever we eat, the digestive system breaks each food or substance into its primary "non-antigenic" building blocks, thereby averting a potentially harmful immune attack. So, strange as it may seem, antigens that trigger an immune response when they are injected can encourage immune system tolerance when taken orally. Furthermore, this reaction is directed solely at the specific antigen being fed; wholesale immunosuppression, which can leave the body open to a variety of infections, does not occur. Studies have shown that when rodents with EAE are fed myelin protein antigens, they experience fewer relapses. Data from a small, preliminary trial of antigen feeding in humans found limited suggestion of improvement, but the results were not statistically significant. A multi-center trial is being conducted to determine whether protein antigen feeding is effective.

Cytokines

As our growing insight into the workings of the immune system gives us new knowledge about the function of cytokines, the powerful chemicals produced by T cells, the possibility of using them to manipulate the immune system becomes more attractive. Scientists are studying a variety of substances that may block harmful cytokines, such as those involved in inflammation, or that encourage the production of protective cytokines.

A drug that has been tested as a depression treatment, rolipram, has been shown to reduce levels of several destructive cytokines in animal models of MS. Its potential as a therapy for MS is not known at this time, but side effects seem modest. Protein antigen feeding, discussed above, may release transforming growth factor beta (TGF), a protective cytokine that inhibits or regulates the activity of certain immune cells. Preliminary tests indicate that it may reduce the number of immune cells commonly found in MS patients' spinal fluid. Side effects include anemia and altered kidney function.

Interleukin 4 (IL-4) is able to diminish demyelination and improve the clinical course of mice with EAE, apparently by influencing developing T cells to become protective rather than harmful. This also appears to be true of a group of chemicals called retinoids. When fed to rodents with EAE, retinoids increase levels of TGF and IL-4, which encourage protective T cells, while decreasing numbers of harmful T cells. This results in improvement of the animals' clinical symptoms.

Remyelination

Some studies focus on strategies to reverse the damage to myelin and oligodendrocytes (the cells that make and maintain myelin in the central nervous system), both of which are destroyed during MS attacks. Scientists now know that oligodendrocytes may proliferate and form new myelin after an attack. Therefore, there is a great deal of interest in agents that may stimulate this reaction. To learn more about the process, investigators are looking at how drugs used in MS trials affect remyelination. Studies of animal models indicate that monoclonal antibodies and two immunosuppressant drugs, cyclophosphamide and azathioprine, may accelerate remyelination, while steroids may inhibit it. The ability of intravenous immunoglobulin (IVIg) to restore visual acuity and/or muscle strength is also being investigated.

Diet

Over the years, many people have tried to implicate diet as a cause of or treatment for MS. Some physicians have advocated a diet low in saturated fats; others have suggested increasing the patient's intake of linoleic acid, a polyunsaturated fat, via supplements of sunflower seed, safflower, or evening primrose oils. Other proposed dietary "remedies" include megavitamin therapy, including increased intake of vitamins B12 or C; various liquid diets; and sucrose-, tobacco-, or gluten-free diets. To date, clinical studies have not been able to confirm benefits from dietary changes; in the absence of any evidence that diet therapy is effective, patients are best advised to eat a balanced, wholesome diet.

Unproven Therapies

MS is a disease with a natural tendency to remit spontaneously, and for which there is no universally effective treatment and no known cause. These factors open the door for an array of unsubstantiated claims of cures. At one time or another, many ineffective and even potentially dangerous therapies have been promoted as treatments for MS. A partial list of these "therapies" includes: injections of snake venom, electrical stimulation of the spinal cord's dorsal column, removal of the thymus gland, breathing pressurized (hyperbaric) oxygen in a special chamber, injections of beef heart and hog pancreas extracts, intravenous or oral calcium orotate (calcium EAP), hysterectomy, removal of dental fillings containing silver or mercury amalgams, and surgical implantation of pig brain into the patient's abdomen. None of these treatments is an effective therapy for MS or any of its symptoms.
Drugs Used to Treat Multiple Sclerosis

Drugs currently available to patients

Steroids Adrenocorticotropic hormone (ACTH) Prednisone Prednisolone Methylprednisolone Betamethasone Dexamethasone Interferons Beta interferons (Avonex, Betaseron) Beta interferon (Rebif)âavailable in Europe only

Some experimental therapies

Alpha interferon Cyclosporine (Sandimmune) Cyclophosphamide (Cytoxan) Methotrexate Azathioprine (Imuran) Linomide (Roquinimex) Cladribine (Leustatin) Mitoxantrone Aminopyridine, derivatives of Copolymer I (Copaxone) Rolipram Interleukin 4 (IL-4) Retinoids Total lymphoid irradiation Monoclonal antibodies Plasma exchange or plasmapheresis Bone marrow transplantation Peptide therapy Various MS vaccines Protein antigen feeding Transforming growth factor beta (TGF) Intravenous immunoglobulin (IVIg)

Are Any MS Symptoms Treatable?

While some scientists look for therapies that will affect the overall course of the disease, others are searching for new and better medications to control the symptoms of MS without triggering intolerable side effects.

Many people with MS have problems with spasticity, a condition that primarily affects the lower limbs. Spasticity can occur either as a sustained stiffness caused by increased muscle tone or as spasms that come and go, especially at night. It is usually treated with muscle relaxants and tranquilizers. Baclofen (Lioresal), the most commonly prescribed medication for this symptom, may be taken orally or, in severe cases, injected into the spinal cord. Tizanidine (Zanaflex), used for years in Europe and now approved in the United States, appears to function similarly to baclofen. Diazepam (Valium), clonazepam (Klonopin), and dantrolene (Dantrium) can also reduce spasticity. Although its beneficial effect is temporary, physical therapy may also be useful and can help prevent the irreversible shortening of muscles known as contractures. Surgery to reduce spasticity is rarely appropriate in MS.

Weakness and ataxia (incoordination) are also characteristic of MS. When weakness is a problem, some spasticity can actually be beneficial by lending support to weak limbs. In such cases, medication levels that alleviate spasticity completely may be inappropriate. Physical therapy and exercise can also help preserve remaining function, and patients may find that various aidsâsuch as foot braces, canes, and walkersâcan help them remain independent and mobile. Occasionally, physicians can provide temporary relief from weakness, spasms, and pain by injecting a drug called phenol into the spinal cord, muscles, or nerves in the arms or legs. Further research is needed to find or develop effective treatments for MS-related weakness and ataxia.

Although improvement of optic symptoms usually occurs even without treatment, a short course of treatment with intravenous methylprednisolone (Solu-Medrol) followed by treatment with oral steroids is sometimes used. A trial of oral prednisone in patients with visual problems suggests that this steroid is not only ineffective in speeding recovery but may also increase patients' risk for future MS attacks. Curiously, prednisone injected directly into the veinsâat ten times the oral doseâdid seem to produce short-term recovery. Because of the link between optic neuritis and MS, the study's investigators believe these findings may hold true for the treatment of MS as well. A follow-up study of optic neuritis patients will address this and other questions.

Fatigue, especially in the legs, is a common symptom of MS and may be both physical and psychological. Avoiding excessive activity and heat are probably the most important measures patients can take to counter physiological fatigue. If psychological aspects of fatigue such as depression or apathy are evident, antidepressant medications may help. Other drugs that may reduce fatigue in some, but not all, patients include amantadine (Symmetrel), pemoline (Cylert), and the still-experimental drug aminopyridine.

People with MS may experience several types of pain. Muscle and back pain can be helped by aspirin or acetaminophen and physical therapy to correct faulty posture and strengthen and stretch muscles. The sharp, stabbing facial pain known as trigeminal neuralgia is commonly treated with carbamazapine or other anticonvulsant drugs or, occasionally, surgery. Intense tingling and burning sensations are harder to treat. Some people get relief with antidepressant drugs; others may respond to electrical stimulation of the nerves in the affected area. In some cases, the physician may recommend codeine.

As the disease progresses, some patients develop bladder malfunctions. Urinary problems are often the result of infections that can be treated with antibiotics. The physician may recommend that patients take vitamin C supplements or drink cranberry juice, as these measures acidify urine and may reduce the risk of further infections. Several medications are also available. The most common bladder problems encountered by MS patients are urinary frequency, urgency, or incontinence. A small number of patients, however, retain large amounts of urine. In these patients, catheterization may be necessary. In this procedure, a catheter or drainage tube is temporarily inserted (by the patient or a caretaker) into the urethra several times a day to drain urine from the bladder. Surgery may be indicated in severe, intractable cases. Scientists have developed a "bladder pacemaker" that has helped people with urinary incontinence in preliminary trials. The pacemaker, which is surgically
implanted, is controlled by a hand-held unit that allows the patient to electrically stimulate the nerves that control bladder function.

MS patients with urinary problems may be reluctant to drink enough fluids, leading to constipation. Drinking more water and adding fiber to the diet usually alleviates this condition. Sexual dysfunction may also occur, especially in patients with urinary problems. Men may experience occasional failure to attain an erection. Penile implants, injection of the drug papaverine, and electrostimulation are techniques used to resolve the problem. Women may experience insufficient lubrication or have difficulty reaching orgasm; in these cases, vaginal gels and vibrating devices may be helpful. Counseling is also beneficial, especially in the absence of urinary problems, since psychological factors can also cause these symptoms. For instance, depression can intensify symptoms of fatigue, pain, and sexual dysfunction. In addition to counseling, the physician may prescribe antidepressant or antianxiety medications. Amitriptyline is used to treat laughing/weeping syndrome.

Tremors are often resistant to therapy, but can sometimes be treated with drugs or, in extreme cases, surgery. Investigators are currently examining a number of experimental treatments for tremor.

* What is Multiple Sclerosis?
* Who Gets MS?
* What Causes MS?
* The Immune System
* Genetics
* What is the Course of MS?
* Can Life Events Affect the Course of MS?
* What are the Symptoms of MS?
* How is MS Diagnosed?
* Can MS be Treated?
* What Recent Advances Have Been Made in MS Research?
* Glossary
* Information Resources
* Research Centers
* Multiple Sclerosis News

source:
the National Institute of Neurological Disorders and Stroke

Disease Specific Health News

[LINK] [LINK] [LINK] [LINK] [LINK]

RE: [MS_Community] The Demonized Seed by Lee Green

2007-08-29 16:28:38

There is no doubt that hemp is no more dangerous than alcohol and can and
does help those people with illness that can be improved by it. However, to
say that it is no more dangerous than alcohol is not saying a lot. There
real answer is, not making hemp illegal, but with so many innocent people
dieing every year from drunk drivers, why don't we control alcohol more. We
can't prosecute drunk drivers with murder or even manslaughter because they
didn't know what they were doing, but I and others say, if that is the case,
why do we let them use cars then? If you kill someone with a car, why let
them drive it? Hemp is not dangerous, but it is detrimental to good health
and welfare. Young people who enjoy hemp recreationally seldom achieve
those goals that would make them self supporting. Everyone knows of
exceptions, but they are exceptions.
The demons are those people who would de-demonize hemp. It is bad because
it is subtle.
-Dave

DO THE NEXT THING

2007-08-29 11:41:36

YOUR DAILY MOTIVATION
Monday, January 19, 2004

Sure to follow

2007-08-29 02:37:52

Adapted from The Daily Motivator

Monday, January 19, 2004

Sure to follow

Everything you have ever achieved represents just a fraction of your full potential. Just imagine how much higher you can go!

All the things you already know comprise just a small portion of the knowledge that is available to you. Just imagine what will happen when you make the effort to broaden your horizons!

If your expectations are based only on what you have already done, they are way too low. Raise your expectations to better match your incredible potential.

Most of what you become will flow naturally from what you expect yourself to be. The higher your expectations the more of your best possibilities you will fulfill.

If you expect that today will be no better than yesterday, this is exactly what will happen. When you expect to regularly reach new vistas of achievement and experience, they will surely come.

Always keep your expectations higher than your reality, and the reality of your life will be sure to follow.

-- Ralph Marston

[INLINE]

~Joyce [INLINE]
How can you tell when you are out of invisible ink?

Fw: [jjworld] Niagara Falls meet - May 2004

2007-08-28 21:39:17

-----Forwarded Message-----
From: Jooly's Joint <jooly@...
Sent: Jan 18, 2004 10:37 AM

Montel on CBS

2007-08-28 15:06:44

Thank you, Danka.

http://www.cbsnews.com/stories/2004/01/08/earlyshow/leisure/books/main592184.shtml

[INLINE]
~Joyce
What is the speed of dark?

Has this happened to you?

2007-08-28 09:26:16

[INLINE]

~Joyce
What is the speed of dark?

MS was Krolich's cue to follow his dream

2007-08-28 02:33:46

MS was Krolich's cue to follow his dream

Fabric of your life

2007-08-27 22:05:48

Adapted from The Daily Motivator

Sunday, January 18, 2004

Fabric of your life

Where has the time gone? It has not gone but has been going and continues to go into making you who you are. The moments, hours, months and years seem to pass by at an ever-quickening pace. They are filling you up instead of simply passing you by.

You are busy becoming who you will become and expressing who you are. As time moves past it is never lost, but it is woven forever into the fabric of your life.

It is never too early nor too late to fully live the moment that is here right now. The more you make of it the more valuable it will always be to you.

The clock just keeps on ticking, and what it measures is what you are continuing to gain. You always have the opportunity to make this moment, day and year even better than the last and better than ever before.

Time is yours in which to live, grow, love and experience. The more of it you have known the richer you become.

-- Ralph Marston

[INLINE]

~Joyce [INLINE]
What's the speed of dark?

The Demonized Seed by Lee Green

2007-08-27 15:11:09

As a Recreational Drug, Industrial Hemp Packs the Same Wallop as Zucchini. So
Why Does
the U.S. Drug Enforcement Agency Continue to Deny America This Potent Resource?
Call It
Reefer Madness.
On an otherwise unremarkable day nearly 30 years ago, in a San Fernando Valley
head
shop, an ordinary man on LSD had an epiphany. The one thing that could save the
world,
it came to him, was hemp.
Thunderbolts come cheap on LSD, but this one looked good to Jack Herer even
after his
head cleared. The world needed relief from its addiction to oil and
petrochemicals.
From deforestation and malnutrition. From dirty fuels, sooty air, exhausted
soils and
pesticides. The extraordinary hemp plant could solve all those problems. Herer
was sure
of it. Thus began his journey as a heralding prophet.
For 12 years, Herer expanded his knowledge of hemp, burrowing deep into U.S.
government
archives and writing about his discoveries in alternative newspapers and
magazines. He
self-published "The Emperor Wears No Clothes," an impassioned rant for the
utilitarian
virtues of cannabis sativa, the ancient species that gives us both hemp and
marijuana,
which are genetically distinct. Experts agree that in contrast to marijuana,
cannabis
hempor industrial hemp as it is often calledhas no drug characteristics.
Herer's book, quirky but substantive enough to be taken seriously, inspired
thousands
and became an underground classic. The author has issued 16 printings over the
years,
revising and updating his material 11 times. Today, Herer is widely credited
with
launching the modern hemp movement, a persistent campaign by an eclectic
coalition of
environmentalists, legislators, rights activists, farmers, scientists,
entrepreneurs
and others to end the maligned plant's banishment and tap its potential as a
natural
resource.
Despite the book's over-the-top exuberance and occasional leaps of syllogistic
fancyor
more likely because of themit has sold 665,000 copies in seven languages. Or is
it
635,000 copies in eight languages? The prophet isn't sure as he pads across the
abused
gray carpet of his two-bedroom Van Nuys apartment, a flower-child domicile to
which the
benefits of even the most rudimentary housekeeping remain foreign. Beard
unkempt, hair
askew, Herer matches the décor. "How can they make the one thing that can save
the
world illegal?" he asks, no less astonished by this paradox now than he was
three
decades ago.
Herer's question is essentially the same one hemp advocates in the U.S. have
been
asking with mounting consternation for the past decade. They are asking it now
with new
urgency in response to the Drug Enforcement Agency's latest foray against hemp,
an
attempt since 2001 to ban all food products containing even a trace of hemp,
even
though the foods are not psychoactive. The California-based Hemp Industries
Assn. and
seven companies that make or sell hemp products won a reprieve for the industry
in
June, when the U.S. 9th Circuit Court of Appeals ruled the DEA's efforts
"procedurally
invalid." But the matter remains in litigation, and the hemp issue continues to
confound policymakers.
California's Legislature passed a bill on behalf of hemp not long ago that, in
its
final, watered-down form, could hardly have been less ambitious. Assembly Bill
388,
approved in 2002 by wide margins in both chambers, merely requested that the
University
of California assess the economic opportunities associated with several
alternative
fiber crops. But because one of the crops was cannabis hemp, then-Gov. Gray
Davis
vetoed the measure, leaving California uncharacteristically behind the curve on
a
progressive issue that many other states and nations have embraced in recent
years.
If all or even most of the oft-cited claims for hemp are true, the substance may
know
no earthly equal among nontoxic renewable resources. If only half the claims are
true,
hemp's potential as a commercial wellspring and a salve to creeping eco-damage
is still
immense. At worst it is more useful and diverse than most agricultural crops.
Yet from
the 1930s through the 1980s, many countries, influenced by U.S. policies and
persuasion, banished cannabis from their farmlands. Not just marijuana, but all
cannabisthe baby, the bath water, all of it.
Confronted with declining demand for their tobacco, farmers in Kentucky, where
hemp was
the state's largest cash crop until 1915, argue that commercial hemp could help
save
their farms. California doesn't face that particular dilemma but, in theory,
hemp
agriculture eventually could bestow innumerable benefits on the state, from tax
revenues to healthier farm soils and reductions in forest logging for wood and
paper.
Environmentally benign hemp crops could replace at least some of California's 1
million
acres of water-intensive and chemical-laden cotton.
Since taking root in the early 1990s, the hemp movement has made great progress
around
the world. Unfenced fields of the tall, cane-like plants flourish in Austria,
Italy,
Portugal, Irelandthe entire European Union. Great Britain reintroduced the crop
in
1993. Germany legalized it in 1996. Australia followed suit two years later, as
did
Canada. Among the world's major industrial democracies, only the United States
still
forbids hemp farming. If an American farmer were to fill a field with this
drugless
crop, the government would consider him a felon. For selling his harvest he
would be
guilty of trafficking and would face a fine of as much as $4 million and a
prison
sentence of 10 years to life. Provided, of course, it is his first offense.
This for a crop as harmless as rutabaga.
Prejudiced by nearly 70 years of government and media propaganda against all
things
cannabis, most Americans have no idea that hemp crops once flourished from
Virginia to
California. Prized for thousands of years for its fiber, the plant rode commerce
from
Asia to Europe in the first millennium and sailed to the New World in the
second.
American colonists grew it in the early 1600s. Two centuries later, hemp was the
nation's third-largest agricultural commodity. The U.S. census of 1850 counted
8,327
hemp plantations, and those were just the largest ones. California farmers
cultivated
it at least into the 1930s.
If all this seems hazy to the American mind, it's because cannabis hemp slowly
vanished
from our farms and our cultural memory. The abolition of slavery following the
Civil
War put hemp at a competitive disadvantage because its harvest and processing
required
intensive labor. The industry slowly declined to the brink of extinction as
cotton
captured the fiber market, but by the mid-1930s new machinery could efficiently
extract
hemp's fibers from its stalk, and the plant was poised for economic recovery.
The
February 1938 issue of Popular Mechanics hailed it as the "New Billion-Dollar
Crop,"
while a concurrent issue of Mechanical Engineering deemed hemp "The Most
Profitable and
Desirable Crop That Can Be Grown."
The trail grows murkier here, but the crucial element of this buried history
lies
beyond dispute: In 1935, the U.S. governmentin particular the Bureau of
Narcotics
(part of the Treasury Department and a predecessor to the present-day U.S. Drug
Enforcement Agency) and its chief, Harry J. Anslingerembarked on an
inflammatory
campaign to convince the public of the evils of marijuana.
The Hearst newspapers had acquired a taste for sensationalistic headlines and
lurid
stories about Mexicans and "marijuana-crazed Negroes" assaulting, raping and
murdering
whites. It was all nonsense, but Anslinger shamelessly parroted these myths and
concocted his own in congressional testimony and in speeches and articles,
branding
marijuana the "worst evil of all." In a 1937 magazine piece titled "Marijuana,
the
Assassin of Youth," he blamed suicides and "degenerate sex attacks" on the drug.
"Marijuana is the unknown quantity among narcotics," he wrote. "No one knows,
when he
smokes it, whether he will become a philosopher, a joyous reveler, a mad
insensate, or
a murderer." Prior to such calculated misstatements, few Americans had smoked
marijuana. Most had never even heard of it.
The government's motives for its attack on marijuana remain unclear. Researchers
have
proffered theories ranging from collusion with corporations threatened by hemp's
commercial potential to moralistic fervor and bureaucratic thirst for domain
once
Prohibition ended in 1933. Regardless of motives, the ensuing stigmatization,
red tape,
state and federal controls, punitive taxes and misconceptions about marijuana's
nature
and its relationship to hemp doomed any chance that hemp would be resurrected as
an
agricultural crop. Fewer and fewer farmers were willing to grow it, and
manufacturers
sought other resources for rope, twine, nets, sailcloth, textiles, paint and
other
fiber and oil products for which hemp is well suited. The government briefly
reversed
course during World War II, launching an aggressive "Hemp for Victory" campaign
that
implored U.S. farmers to grow the crop to alleviate wartime materials shortages.
But
after the war, hemp again faded into oblivion.
In 1957, a Wisconsin farmer harvested the last legal commercial hemp crop in
America.
The government's outright prohibition of the crop, a nonissue until interest in
hemp
renewed in the early 1990s, was formalized in 1971 with implementation of the
Controlled Substances Act, the centerpiece of U.S. drug policy.
Today's reawakened market faces an uphill battle in the U.S., not just because
source
materials can't be grown here but because decades of enforced hibernation have
left the
industry light-years behind in technology, infrastructure, research and
development,
marketing and public acceptance. Hemp Industries Assn., a consortium of about
250
importers, manufacturers, wholesalers and retailers, says that in the past
decade the
North American market has gone from virtually nothing to an estimated $200
million. Not
bad under the circumstances, but still a pittance for a plant that could clothe
and
house us, build and fuel our cars, enhance our diets and keep the front gate
from
squeaking.
Hemp has attracted many passionate advocates over the years simply because of
its
relation to the illegal drug. But a glance at hemp's résumé makes it clear why a
mere
vegetable could inspire a devout constituency that transcends the
counterculture.
Hemp's products, its proponents insist, are interchangeable with those from
timber or
petroleum. The fiber volume supplied by trees that take 30 years to grow can be
harvested from hemp just three or four months after the seeds go into the
groundand on
half the land. Hemp requires no herbicides, little or no pesticide, and it grows
faster
than almost any other plant: from seed to 10 feet or taller in just a few
months.
Unlike most crops, it actually enriches rather than depletes the soil. As a
textile it
has proven stronger than cotton, warmer than linen, comfortable to wear and
durable. As
a building material, its extraordinarily long fibers test stronger than wood or
concrete. As a nutrient it contains one of nature's most perfectly balanced
oils, high
in protein, richer in vitamin E than soy and possessing all eight essential
fatty
acids.
But because hemp contains traces of the chemical intoxicant known as
tetrahydrocannabinol, or THC, the U.S. government lists cannabis as a Schedule I
drug,
a category reserved for the most dangerous and medically useless drugs.
Methamphetamine, PCP and cocaine don't warrant that classification, but hemp
does,
right alongside heroin and LSD. The word hemp doesn't actually appear on the
list, but
the drug-war establishment, particularly the instrumental DEA, behaves as though
it
does by recognizing no distinction between varieties of cannabis.
The DEA sometimes seems bent on fomenting confusion. Two years ago, during his
brief
tenure as head of the agency, Asa Hutchinson stated that "many Americans do not
know
that hemp and marijuana are both parts of the same plant and that hemp cannot be
produced without producing marijuana." One reason many Americans do not know
this is
because it's not true. That's like saying beagles and collies are both parts of
the
same dog and that beagles cannot be produced without producing collies.
Unmoved by logic, accepted nomenclature or the realities of plant genetics, the
DEA
insists that all cannabis is marijuana. Does the agency also consider industrial
hemp
grown legally outside the U.S. to be marijuana? "Yes, we do," says Frank
Sapienza, the
agency's chief of drug and chemical evaluation. Since more than 30 other
countries
manage to distinguish between marijuana and industrial hemp and allow their
farmers to
grow hemp, one wonders what they know that the U.S. doesn't. "I'm not going to
comment
on what other countries do," Sapienza says.
The DEA argues that the revival of hemp farming in the U.S. will somehow
increase the
availability, use and public acceptance of marijuana. Hemp activists dismiss
this
argument out of hand, as does one of their most formidable allies, former CIA
Director
James R. Woolsey. Hailing from the political right, Woolsey vehemently opposes
any
loosening of America's marijuana laws. But in his experience, he says, most
people,
once they become informed about hemp, see no justification for America's
prohibition
against the crop. "They understand that there's not been any increase in use of
marijuana in, say, Europe or Canada as a result of industrial hemp cultivation.
It's
one of those issues in which there are no real substantive arguments on the
other
side."
Sapienza points out, as DEA officials often do, that the agency merely enforces
the
law. In truth, though, the DEA also interprets the law, creates exemptions to it
and
makes judgments that determine how statutory abstractions translate to
on-the-ground
realities. A case in point is the agency's declaration in late 2001 that all
edible
hemp productscereals, health bars, sodas, salad oils and the like, products
sold in
the U.S. for yearsare illegal. Hundreds of retailers were given a few months to
get
such items off their shelves. If a federal court hadn't intervened, a
multimillion-dollar industry would have been wiped out by a DEA decision to
reinterpret
existing law. For now, edible hemp products remain legal and commercially
available in
the U.S., pending a 9th Circuit court ruling expected sometime this year.
Despite hemp's stigma, state legislatures in recent years have been surprisingly
bold
in their willingness to address the issue. Though Davis vetoed California's 2002
bill
requesting research, in 1999 both the state Assembly and the California
Democratic
Party approved unambiguous resolutions supporting hemp commercialization. Twelve
other
states have passed similar resolutions or bills. Since 1997, North Dakota,
Minnesota,
Montana, West Virginia and Maryland have legalized cultivation, and in 2000, the
National Conference of State Legislatures passed a resolution urging the federal
government to clear the barriers to domestic hemp production. But entrenched
federal
opposition renders all these political machinations meaningless beyond symbolic
value.
The DEA, which is within the Justice Department, justifies its unbending posture
on
hemp with assertions that legal hemp agriculture would provide camouflage for
illegal
pot growers. From the air or at a distance, the agency says, industrial hemp and
marijuana are virtually indistinguishable.
"The DEA is wrong," says Indiana University professor emeritus Paul Mahlberg, a
plant
cell biologist who has studied cannabis for more than 25 years and is conducting
research on 150 different strains, both hemp and marijuana. "Hemp plants are
tall, 8 to
20 feet. Marijuana plants in the field are shorter." And cultivated hemp grows a
slender, nearly leafless lower stem, whereas marijuana strains are bred to be
"Christmas tree-like in appearance," with abundant leaves, glands and flowers in
which
are stored the intoxicating THC.
Marijuana's bushiness requires far more space per plant, says John Roulac, a
compost
expert and owner of the Sebastopol, Calif., health-food company Nutiva, which
imports
sterilized hemp seed from Canada for nutrition bars. From the ground or the air,
a hemp
crop looks significantly denser than a marijuana crop. "In a square yard, you
might
grow one or two marijuana plants, whereas with hemp you might have 100 plants,"
Roulac
says.
The argument about physical appearance should be a nonissue, hemp advocates say,
given
that the last place a marijuana grower would want to locate his drug crop is in
or near
a hemp field. The consensus among cannabis experts, supported by the logic of
plant
genetics and field studies, is that cross-pollination would sabotage the pot
grower's
efforts, causing his next generation of marijuana to be only half as potent.
This
genetic convenience delights hard-line anti-marijuana types such as Woolsey, the
former
CIA chief. He was skeptical about pro-hemp arguments when he first heard them.
"But
then I got into the science of it a bit, and it was quite clear to me that not
only is
[hemp cultivation] a good idea, it's a major headache for marijuana [growers],"
he says
with an impish laugh. If it were up to Woolsey, tall, lush fields of industrial
hemp
would be greening America, filling the sky with airborne pollen and frustrating
marijuana growers everywhere.
The DEA flatly rejects the idea that a hemp field would degrade any marijuana in
the
vicinity. A spokeswoman for the agency recently maintained that "it cannot be
said with
any level of certainty that a cannabis plant of relatively low THC content will
necessarily reduce the THC content of other plants grown in close proximity."
Hemp may be absurdly intertwined with marijuana, but the DEA could ease
restrictions on
hemp simply by removing marijuana from its list of most dangerous drugs. That
may sound
radical to a public conditioned to believe marijuana is as dangerous as heroin,
but
Mitch Earleywine, a drug addiction expert and associate professor of clinical
psychology at USC, doesn't think so. In reviewing about 500 marijuana studies
for his
recent book "Understanding Marijuana: A New Look at the Scientific Evidence,"
Earleywine found little or no scientific evidence for any of the most prominent
allegations against the drug, least of all that it causes violent or aggressive
behavior, decreases motivation or acts as a gateway to harder drugs. It is
addictive,
he says, but "it's nowhere near the caliber of, say, heroin, alcohol, nicotine,
caffeine, any of those drugs." Should it be a Schedule I controlled substance?
"In all
honesty, the idea that it has to be scheduled at all might be up for question,"
he
says. "Americans are just too freaked out about [marijuana]."
One of the most persistent charges against the hemp lobby is that it's really
just a
marijuana movement in disguise.
"Let's not play dumb here," says America's reigning drug czar, John P. Walters
of the
White House Office of National Drug Control Policy. "It is no coincidence that
proponents of marijuana have invested a great deal of time and money in an
effort to
expand hemp cultivation. They do this not, one presumes, from any special
interest in
industrial fiber resources, but from an earnest belief that more widespread
domestic
hemp cultivation will make the cultivation and distribution of marijuana easier,
and
that a legal hemp industry would frustrate law enforcement efforts against
marijuana
trafficking."
Unquestionably, the hemp and marijuana crowds overlap. Most pro-marijuana people
think
American farmers should be able to grow hemp, and many in the hemp movement
condemn
America's war on drugs and its marijuana laws. But the government's claim that
virtually everyone pressing for hemp cultivation has a hidden agenda amounts to
a sort
of psychotropic McCarthyism. Eric Steenstra represents a Hungarian hemp textile
producer and runs an Internet-based advocacy organization called Vote Hemp.
"Industrial
hemp is a peripheral issue to the drug war, but it has gotten caught up in it,"
he
says. "It's frustrating. You can't discount this movement as being just a bunch
of
stoned hippies following the Grateful Dead."
Quips former Kentucky Gov. Louie B. Nunn: "Should we listen when Canada's Royal
Mounted
Police report no problems regulating hemp, or are they also working to legalize
marijuana?"
Yes, there is Woody Harrelson, but the class photo also includes Nunn, Ralph
Nader,
Hugh Downs, Ted Turner and Woolsey, who sits on the board of directors of the
North
American Industrial Hemp Council, an advocacy organization founded in 1995.
"They've tried to tie us to the marijuana movement all along, and they can't get
it
done," says Erwin "Bud" Sholts, chair of the hemp council. Sholts is a
69-year-old
farmer whose career as an alternative crop researcher for the state of Wisconsin
convinced him America should consider hemp a valuable resource, not an outlaw
crop. "If
the rest of the world wants to make marijuana legal, that's fine, but we're
interested
in the agriculture crop."
When Jack Herer began his quest to emancipate hemp, he just assumed that
everyone would
find the essential facts about the plant's qualities so compelling that the
battle
would be won in six monthstwo years, tops. That was 29 years ago.
One of the many people intrigued by Herer's book was Dave West, a Midwest plant
breeder
with a doctorate in breeding and genetics. His curiosity about hemp had already
been
piqued by something he witnessed in the mid-1980s as he toiled one sweltering
day in a
Wisconsin cornfield. A helicopter suddenly appeared low in the sky, then hovered
over
an adjacent field while several men rappelled to the ground. It was a
drug-enforcement
operation going after wild marijuana. "Which, as a plant breeder and as somebody
who
grew up in Wisconsin, I knew was preposterous," West recalls. "I knew this was
feral
hemp and nobody wanted it, and that's why it was growing as a weed out there and
nobody
was picking it."
Since 1979, at a cost of millions of dollars annually ($13.5 million in 2002),
the DEA
has orchestrated an ambitious campaign of "marijuana eradication." The scene
West
observed in the cornfield was, and still is, a common one: a marijuana
eradication team
eradicating not marijuana but harmless feral hemp, often called "ditchweed."
Escaped
remnants from commercial hemp harvests of long ago still grow along railroad
tracks and
fence lines and in fields and culverts throughout America's heartland. Justice
Department statistics show that year after year, as much as 98% of the "wild
marijuana"
the DEA pulls up is actually ditchweed.
"Here was an agency of the government that was selling this line"calling
ditchweed
"marijuana""that was obviously a perversion of reality," West says. "This is a
genetic
resource issue. Instead of collecting, preserving and working with it, we're
sending
the DEA to rappel down from helicopters to pull it out and destroy it wherever
they can
find it."
From July 1999 until recently, West presided over a state-sanctioned,
corporate-funded
quarter-acre test plot of cannabis on the Hawaiian island of Oahu. He possessed
the
only DEA license to research cannabis for industrial use. To meet DEA
requirements, he
fortified his site with better security than you'd find at a typical Russian
nuclear
stockpile. Ten-foot-high fencing topped with barbed wire, an alarm siren,
infrared beam
perimeter. You'd think he was manufacturing enriched plutonium.
For nearly four years West worked to develop a strain of cannabis ideal for
cultivation
as industrial hemp in the United States. Funding proved difficult given that
investors
and grants don't tend to find their way to research for a crop that has been
illegal in
this country for 33 years. But when he shut down the project last fall, West
says, his
decision wasn't prompted so much by money woes as by the federal government's
"strong
and entrenched opposition to hemp." In a written statement he handed to DEA
agents
Sept. 30, the day he walked off the property for good, he left no doubt about
his
feelings. "I quit in protest," his statement said.
A few months earlier, he had begun girding himself for the unpleasant task of
eliminating the very thing his labors had created. "When I pull the plug," he
lamented
with wry sarcasm, "the DEA will require that the seed be destroyed. It is, after
all a
narcotic with no known redeeming use here on this flat earth."
The DEA agents did indeed require West to destroy the seed. The government shows
no
signs that it will allow industrial hemp to be grown in the United States
anytime soon.
* Sidebar: A Cannabis Primer
Because they're often used interchangeably, the terms cannabis, hemp and
marijuana can
be confusing. While cannabis encompasses all varieties of the species, hemp,
often
called industrial hemp, has come to mean a few dozen nonintoxicating varieties
of
cannabis bred and cultivated for commercial ends: clothing, paper, food,
biofuels,
biodegradable plastic, building materials, automobile parts, insulators, paints,
lubricantsthe list of possibilities goes on.
Marijuana, on the other hand, refers strictly to the cannabis drug plant, of
which
there exist endless varieties differentiated by the amount of intoxicating
substances
they contain, notably tetrahydrocannabinol (THC). Today virtually all strains of
cannabis are the product of human alteration, manipulated by scientists,
breeders and
drug dealers to increase or decrease THC content and other characteristics to
suit
their purposes.
Mitch Earleywine, a drug addiction expert at USC, says marijuana typically
contains a
THC concentration of 2% to 5%, and some strains have measured as much as 22% or
higher.
By contrast, industrial hemp has been reduced by breeders to 0.3%, a trifle that
authorities agree produces no psychoactive effect.
* Sidebar: The Myth of Hemp Licensing
If you want to apply for a license to grow commercial hemp, you must solicit the
U.S.
Drug Enforcement Agency. The DEA consistently claims that no prohibition on hemp
farming exists in this country, as if to suggest that all one need do is file
the
proper paperwork and make a reasonable case.
"We don't have any preconceived notions that we are or are not going to approve
or deny
any application," says Frank Sapienza, the DEA's chief of drug and chemical
evaluation,
implying that every case is a judgment call that could go either way.
Nonetheless, the agency has rejected every application it has ever received. How
many?
There's no tellingliterally. The agency will say only that "the DEA does not
have
records of the number of applications received for such activities"an
extraordinary
claim from an organization that documents every marijuana plant that it and
cooperating
law enforcement agencies uproot from U.S. soil. (In 2001, the total was
3,304,760
plants, though nearly all of them were feral hemp, or "ditchweed," not
marijuana.)
Any denial that there is a U.S. hemp prohibition contradicts a salient fact: The
DEA
has never approved an application for commercial hemp cultivation.
Lee Green last wrote for the magazine about secular ethicist Michael Josephson.
The Demonized Seed
http://www.freedomtoexhale.com/herer.htm
Source: Los Angeles Times (CA)
Author: Lee Green, Special to The Times
Published: January 18, 2004
Contact: letters@...
Website: http://www.latimes.com
Jack Herer
http://www.jackherer.com
Electric Emperor
http://www.electricemperor.com
Emperor of Hemp
http://www.emperorofhemp.com/
FTE's Hemp Links
http://freedomtoexhale.com/hls.htm
CannabisNews Hemp Archives
http://cannabisnews.com/news/list/hemp.shtml
******************************************
Hemp Products
http://www.cannabinoid.com/wwwboard/politics/binaries/29/29799.gif
Hemp applications
http://www.cannabinoid.com/wwwboard/politics/binaries/29/29800.gif
The Invisible Prohibition
http://www.sumeria.net/politics/invpro.html
Shadow of the Swastika
http://www.sumeria.net/politics/shadv3.html
******************************************
Ganja/hemp lnfolinx
http://makeashorterlink.com/?S11B23B45
Hemp vs Cotton
http://makeashorterlink.com/?P21931295
Hemp vs Dioxins
http://makeashorterlink.com/?Y23D21B45
Organic Cannabis/Tobacco vs Chemical Cigarettes
http://makeashorterlink.com/?V1E931555
Applicable Information
http://makeashorterlink.com/?S43F259D6
Fear in the fields: How hazardous wastes become fertilizer
http://makeashorterlink.com/?M23C12B45
******************************************
=====
Safe Sacramental Cannabis, Food, Fuel, Fiber, FARM-aceuticals
Hardrug, Booze & Petro-Chem Alternative
Eliminated by Legislation and Administrated Education Depravation!
Welcome
http://www.angelfire.com/ca7/ddc/index.html

things to revisit!

2007-08-27 10:52:23

HI-IT HAS BEEN AWHILE AND I'M TRYING TO CATCH UP. I AM TRYING OUT A DAILY CAREGIVER FOR 3 HOURS A DAY-I HAVE MIXED FEELINGS. I ALWAYS SAID I NEEDED A WIFE BUT IT IS SO STRANGE EXCEPTING THE HELP. I CAN EASILY ACCEPT MY SON'S HELP, BUT I FEEL LAZY AND STRANGE ACCEPTING HELP FROM OTHER'S. THE ONLY WAY I REASON MY WAY AROUND THIS FEELING IS TO TELL MYSELF I'M PAYING HARD EARNED $$ FOR THIS-SO ASK FOR WHAT YOU NEED! I JUST HAD TO TRAIN OF THOUGHT THIS, SO BEAR WITH ME! AND I HATED THAT MOVIE-I FELT LIKE HOLLYWOOD WAS SELLING US A BILL OF GOODS! TO MAKE LIFE EASIER IN OUR LOVED ONES-MOVE OUT AND GIVE IT OVER-I AGREE WHAT EVER HAPPENED TO VOWS? I BELIEVE IN TAKING CARE OF ME AND NOT 'BURDENING' OTHERS-BUT THIS WENT TOO FAR FOR ME! I JUST RE-READ 'FARENHEIT 451' WHOA-IT IS SO PERTAINATE TO TODAYS EVENTS IT IS A WEIRD! although written in 1952 as sci-fi by bradbury, when the wife's zoned out to ther big screen tvs and were discussing how they voted in the last election for
the 'most handsome' candidate--it was a deja vue experience! i would love to be able to memerize a book but i just pray to remember the word i need! GOOD READ! I AM NOW READING 'THE SECRET LIFE OF BEES'--BUT GUESS I NEED SOME PROVIGIL CAUSE I KEEP FALLING ASLEEP! more later=time to re-charge, ny
'bats' have been low! paula from oregon

THINGS TO READ:
She had been shopping with her Mom in Wal-Mart. She must have been 6 years old, this beautiful red haired, freckle faced image of innocence. It was pouring outside. The kind of rain that gushes over the top of rain gutters, so much in a hurry to hit the earth it has no time to flow down the spout. We all stood there under the awning and just inside the door of the Wal-Mart. We waited, some patiently, others irritated because nature messed up their hurried day. I am always mesmerized by rainfall. I got lost in the sound and sight of the heavens washing away the dirt and dust of the world. Memories welcome reprieve from the worries of my day. Her voice was so sweet as it broke the hypnotic trance we were all caught in "Mom, let's run through the rain," she said. "What?" Mom asked. "Let's run through the rain!" She repeated. "No, honey. We'll wait until it slows down a bit," Mom replied. This young child waited about another minute and repeated: "Mom, let's run through the
rain."
"We'll get soaked if we do," Mom said. "No, we won't, Mom. That's not what you said this morning," the young girl said as she tugged at her Mom's arm. "This morning? When did I say we could run through the rain and not get wet? "Don't you remember? When you were talking to Daddy about his cancer, you said, 'If God can get us through this, he can get us through anything!" The entire crowd stopped dead silent. I swear you couldn't hear anything but the rain. We all stood silently. No one came or left in the next few minutes. Mom paused and thought for a moment about what she would say. Now some would laugh it off and scold her for being silly. Some might even ignore what was said. But this was a moment of affirmation in a young childs life. A time when innocent trust can be nurtured so that it will bloom into faith. "Honey, you are absolutely right. Let's run through the rain. If GOD lets us get wet, well maybe we just needed washing," Mom said. Then off they ran. We all stood
watching, smiling and laughing as they darted past the cars and yes, through the puddles. They held their shopping bags over their heads just in case. They got soaked. But they were followed by a few who screamed and laughed like children all the way to their cars. And yes, I did. I ran. I got wet. I needed washing. Circumstances or people can take away your material possessions, they can take away your money, and they can take away your health. But no one can ever take away your precious memories...So, don't forget to make time and take the opportunities to make memories everyday.To everything there is a season and a time to every purpose under heaven. A friend sent this to me to remind me of life. Hope you enjoy it. I HOPE YOU STILL TAKE THE TIME TO RUN THROUGH THE RAIN They say it takes a minute to find a special person, an hour to appreciate them, a day to love them, but then an entire life to forget them. Send this to the people you'll never forget and remember to send
it also to the person who sent it to you. It's a short message to let them know that you'll never forget them. If you don't send it to anyone, it means you're in a hurry and that you've forgotten your friends. Take the time to live!!!
* Keep in touch with your friends, you never know when you'll need each other.

to all the "sweet tater's" out there:

http://www.americanbridge.com/taters.htm

Right Now ...
-somebody is thinking of you.
-somebody is caring about you.
-somebody misses you.
-somebody wants to talk to you.
-somebody wants to be with you.
-somebody hopes you aren't in trouble.
-somebody is thankful for the support you have provided.
-somebody wants to hold your hand.
-somebody hopes everything turns out all right.
-somebody wants you to be happy.
-somebody wants you to find him/her.
-somebody is celebrating your successes.
-somebody wants to give you a gift.
-somebody thinks that you ARE a gift.
-somebody loves you.
-somebody admires your strength.
-somebody is thinking of you and smiling.
-somebody wants to be your shoulder to cry on.
SOMEBODY NEEDS YOU TO SEND THIS TO THEM
=====
Never take away anyone's hope. That may be all they have.

Never ending

2007-08-27 04:34:48

Adapted from The Daily Motivator

Saturday, January 17, 2004

Never ending

How can you tell what the best things in life are? They are the things that never end.

For example when you use your creativity, it doesn't get used up; it grows even stronger the more you make use of it. Love is the same way. Give your love, and you will have even more of it.

Live with integrity, and this integrity will grow stronger. Spread joy to others, and joy becomes even more abundant in your own life. Consider courage, grace, peace, kindness, faith and friendship. The more you draw from them the more powerful they become.

The best things in life cannot be lost even though they are often ignored or foolishly rejected. The more you live them the more they are.

-- Ralph Marston

[INLINE]

~Joyce [INLINE]
Do ordinary things in an extraordinary way.

YOU HAVE UNLIMITED CHOICES

2007-08-27 01:24:37

YOUR DAILY MOTIVATION
Saturday, January 17, 2004

YOUR ASPIRATIONS ARE YOUR POSSIBILITIES

2007-08-26 14:44:56

YOUR DAILY MOTIVATION
Friday, January 16, 2004

Fill this moment

2007-08-26 14:33:23

Adapted from The Daily Motivator

Friday, January 16, 2004

Fill this moment

This moment will pass by quickly. You can make it golden before it goes. You can sit there and watch this moment become forever lost, or you can put yourself into this moment and make it forever yours.

This is a moment waiting to be lived. Imagine what can happen when you fill it with love, commitment, courage and focused effort.

It is just a moment, and yet this moment is truly everything you are and the birth of everything you can become. If you waste this moment, you waste the most precious things you have. Fill this moment, the next and the next with the best you can be, and there is no limit to what it can bring you.

This moment is yours to use, but only if you use it now while it is here. Fill it with value and meaning before you send it on its way.

-- Ralph Marston

[INLINE]

~Joyce [INLINE]
Realize that it is never too late.

Fw: Action Alert - Free our people from nursing homes and other institutions

2007-08-26 05:24:34

-----Forwarded Message-----
From: Chris Hilderbrant <childerbrant@...
Sent: Jan 15, 2004 5:01 AM
To: rochestercdr_list@...
Subject: Action Alert - Free our people from nursing homes and other
institutions
<html
<head
<title
Action Alert - Free our people from nursing homes and other institutions
</title
</head
<body bgcolor="#FFFFFF" border="0" marginheight="0" leftmargin="0" topmargin="0"
marginwidth="0"
<table border="0" cellpadding="0" cellspacing="0" width="622" align="center"
<tr
<td height="10" colspan="3"
</td
</tr
<tr
<td colspan="3" align="left"
<font size="2" face="arial,helvetica"
<p
<table width="100%" border="0" cellspacing="0" cellpadding="0"
<tr
<td
Coordinating Council</b
<td rowspan="2" valign="top"
href="http://capwiz.com/rochestercdr/issues/alert/?alertid=4701531"
target="_new"
</tr
<tr
<td
</tr
<tr
<tr
<td colspan="2"
The New York State Assembly still has one appointment to make to the
Most-Integrated Setting Coordinating Council (MISCC). The MISCC is charged with
developing a comprehensive, effectively working plan to implement the Olmstead
decision in New York State. The p